Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Role of proton pump inhibitors in immune checkpoint inhibitor colitis.
Authors
Roshini Pradeep
Midwestern University GME Consortium Residency Program, Cottonwood, AZ
Roshini Pradeep , Afsheen Moshtaghi , Hamza Khan , Ann K Walenga , Neychelle Rocca , Andrzej Piotr Kudelka
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Symptoms, Toxicities, and Whole-Person Care
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 743)
DOI
10.1200/JCO.2024.42.3_suppl.743
Abstract #
743
Poster Bd #
L18
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Tumor- and class-specific patterns of immune-related adverse events (irAEs) of immune checkpoint inhibitors (ICIs): A systematic review (SR).
First Author: Daphne Day
Poster
2024 ASCO Genitourinary Cancers Symposium
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
First Author: Michelle Hsu
Poster
2022 ASCO Annual Meeting
Comprehensive immune profiling unravels evolution of spatial distribution and immune repertoire in tumor microenvironment from primary to metastatic triple-negative breast cancer.
First Author: Weihua Guo
Poster
2022 ASCO Genitourinary Cancers Symposium
FOXP3+ T-cell infiltration is associated with improved outcomes in metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICI).
First Author: Elio Adib